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As you may be one of the many scientists who submitted an
Expression of Interest (EoI) to FP6 you must be wondering
what has happened since June 7, the deadline for submissions.
What follows below is a brief personal account of the con-
sultation process viewed from my participation as a reviewer
in two of the assessment panels within priority theme I, ‘Ge-
nomics and biotechnology for health’, in area 1.1.1.1 ‘Funda-
mental knowledge, and basic tools for functional genomics in
all organisms’.
The consultation process
The Commission received about 15 000 EoIs, of which 3000
were for the life sciences. The number was much larger than
expected, underlining the enormous interest in the scienti¢c
community to actively contribute to the establishment of the
European Research Area (ERA) ^ a vision championed by
Commissioner Philippe Busquin and endorsed by the member
countries.
By consulting the scienti¢c community at large, the Com-
mission wished to identify priority subjects/topics that were
ready for research action using the New Instruments (Inte-
grated Projects, IPs, and Networks of Excellence, NoEs),
and to avoid the high degree of oversubscription that charac-
terised previous FPs.
The review process of the 500 or so EoIs within area 1.1.1.1
was carried out by four panels of expert reviewers who assist-
ed the Commission in (1) identifying key research subject/
topics, (2) assessing the readiness of the scienti¢c community
to submit actions in these areas through the new instruments,
(3) evaluating the European dimension and competitiveness of
such initiatives, and ¢nally (4) de¢ning the scope of the ¢rst
call for proposals.
Each panel consisted of about 15 experts, who as a whole
covered a broad range of expertise in the areas in question.
Each reviewer received 100 EoIs for assessing at home, and
was requested to submit a list of the 15 best EoIs prior to a
2-day meeting in Brussels. All the best EoIs were then com-
piled by the Commission to provide a list of citations that
formed the basis for discussions leading to the selection of
priority subjects/topics that were mature for action. A mem-
ber of the Commission chaired the session, and each of the
experts acted as rapporteurs for six or seven EoIs.
To place the results in the overall context, the review group
was presented with the outcome of previous panels, however,
it was not allowed to change the order of priority set by them.
Moreover, the panel was asked to make recommendations
concerning important subjects/topics, which were not covered
by the received EoIs, but nevertheless were considered essen-
tial to ¢ll gaps.
Next steps: expected calendar of events
Based on the work of the assessment panels in the various
thematic areas, the Commission will now set up the Work
Programmes and de¢ne the scope of the call for proposals.
The document will be presented to the Programme Committee
for approval in October 2002. Scientists who participated in
the assessment may be listed in the document.
Provided that approval is obtained from the applicants, the
abstracts of submitted EoIs, as well as the names of the ex-
perts who participated in the reviewing process, will be made
public on the Internet to enhance transparency.
On condition that the programme is approved, the Com-
mission envisages the following calendar of events:
November 2002: Conference on launch of FP6 and ¢rst
call for proposals
February 2003: Deadline for submission of applications
End of 2003: First contracts
Questions raised at the consultation process
There were several questions raised by the Commission side
concerning the consultation process. Did it represent an im-
provement over the past? What are the positive and negative
features of the exercise? Did it serve its purpose?
The Commission had several options to set the process in
motion; these included the consultation process through EoIs,
the organisation of workshops to de¢ne the subjects/topics, as
well as outside consultation.
Upon having evaluated the options the Commission de-
cided to go for the ¢rst alternative, since this was expected
to engage an important part of the scienti¢c community. In-
deed, the Commission succeeded; the response was over-
whelming to the extent that they were unable to acknowledge
receipt of the applications, as had been promised originally.
There has always been considerable dissatisfaction with the
evaluation process used in the past but this time it may be
di¡erent, as there is a clear determination from the Commis-
sion side to give high priority to scienti¢c excellence. Steps will
be taken to speed up and lighten the rather bureaucratic pro-
cedure for signing and handling contracts, and there will be
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no micromanagement, as the Commission will step back in
the control of the project, by transferring the responsibility to
the manager of the programme.
From now on you may only have your fellow scientists to
blame if your application does not make it to the funding
stage.
There are, however, some aspects that in my opinion should
be improved in the future if the current EoI procedure is to
be adhered to again. My main concern relates to the fact that
not all of the member countries’ applicants/representatives/
reviewers understood what was expected from an EoI. This,
I believe, may have placed some groups in a disadvantaged
position, especially those that included large constellations of
scientists and resources. Also, I would argue that having pan-
els with a broad-based expertise might not be the best way to
proceed in the future, as there were several occasions where I
felt that more concrete expertise might have been necessary.
Fortunately, the ¢rst call is for the ¢rst two years, and the
exercise may be open again in two years time. As such, by
learning from the ¢rst experience, most scientists will be given
a second chance.
Implications of the consultation process
One of the most important outcomes of the exercise is the
fact that there is just not enough money available in FP6 to
reach the goal of structuring research in the life sciences in
Europe. For example, in the area 1.1.1.1 ‘Fundamental
knowledge and basic tools for functional genomics in all or-
ganisms’, which covered gene expression and proteomics,
structural genomics, comparative genomics and population
genetics, bioinformatics, and multidisciplinary functional ge-
nomics approaches to basic biological process, there may be
su⁄cient funds to grant only ¢ve IPs and three NoEs in the
¢rst call. For 2004 we expect three IPs and two NoEs. This is
clearly far from what is needed to remain at the cutting edge
of technology, in a ¢eld which is exploding and which is in
great need of infrastructure. Both the USA and Japan are
making very important investments in the area, and I ^ taking
the current funding situation into context ^ can only foresee a
widening of the gap, which is already painfully evident.
In order to close this gap between Europe and major com-
petitors, the leaders of the European Union (EU) at the sum-
mit in Barcelona this year agreed to increase the RpD and
innovation in the Union to approach 3% of GDP by year
2010. Two thirds of this amount should come from the private
sector. This is a very welcome development, although many
will argue that by 2010 the gap may be too large to be ¢lled
irrespective of how much money is put into the system. We
live in a time where technology and machines become obsolete
soon after they have been developed, and our best students
have a tendency to look at the USA as the place of choice, to
develop their potential.
Today there is much talk about the possibility of creating a
European Research Council. The European Science Founda-
tion (ESF), the European Molecular Biology Conference
(EMBC), as well as other organisations have manifested in-
terest in debating the initiative, and Denmark, which holds
the Presidency of the EU, has taken the lead by organising a
conference in partnership with ESF on the subject (Copenha-
gen on October 7 and 8). Needless to say, the scienti¢c com-
munity awaits with great expectation the outcome of such
discussions.
We are in desperate need to enter into a dialogue with
science policy makers and politicians to ensure that we opti-
mise the use of the resources. To compete we need a vision
and a strategy that takes into account long-term funding as
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